Vaccinex's Decision to Delist from Nasdaq
Vaccinex, Inc. (OTC: VCNX), a biotechnology firm based in Rochester, NY, has announced its decision to delist its common stock from the Nasdaq Stock Market. This decision comes after a suspension of trading that began on December 18. The company, which specializes in the treatment of neurodegenerative diseases and cancer, plans to file Form 25 with the Securities and Exchange Commission for formal removal of its shares.
Reasons Behind the Delisting
The decision follows a notification from the Nasdaq Hearings Panel indicating that the company’s securities were to be delisted. This delisting response is a significant move, as the company has already faced substantial trading disruptions. Vaccinex is now gearing its efforts toward continuing the development of its primary product, pepinemab, aimed at treating Alzheimer’s disease and various cancers.
Focus on Development of Pepinemab
Pepinemab is Vaccinex’s lead therapeutic candidate, designed to tackle Alzheimer’s disease by inhibiting the SEMA4D pathway which plays a crucial role in the progression of neurodegenerative disorders. In clinical studies, including the SIGNAL-AD trial, the potential of pepinemab has been exhibited, suggesting a promising avenue for combatting Alzheimer’s.
Investments in Clinical Studies
Vaccinex is committed to advancing pepinemab through various channels. The company is exploring partnerships and grants to finance its research. The drug is also undergoing clinical trials in combination with KEYTRUDA in head and neck cancers and with BAVENCIO for metastatic pancreatic cancer. The breadth of these studies showcases the company’s ambitious aim to harness pepinemab’s multifaceted capabilities.
Collaboration with Industry Leaders
Vaccinex collaborates with Merck Sharp & Dohme Corp., leveraging their resources in clinical trials. This collaboration has heightened the visibility of their innovative research and development efforts. Through these strategic partnerships, Vaccinex seeks to strengthen its position in the competitive biotech landscape.
Understanding Pepinemab
Pepinemab is classified as a humanized IgG4 monoclonal antibody. Its mechanism targets SEMA4D, a biological factor associated with inflammation in chronic neurological conditions. The rationale behind this therapeutic approach is to restore homeostatic functions in glial cells and dendritic cells that are often disrupted in neurodegenerative diseases and cancer.
Therapeutic Applications and Safety Profile
Clinical trial data indicate that pepinemab has been well-tolerated by patients, illustrating its potential in various indications. The favorable safety profile enhances the viability of pepinemab as a promising candidate for future cancer and neurodegenerative disease therapies.
Investor Communication and Contact Information
For investors seeking more information, they can reach out to Elizabeth Evans, PhD, Chief Operating Officer at Vaccinex, Inc. Elizabeth is accessible for any inquiries or insights about Vaccinex’s ongoing projects and future directions. She can be contacted at (585) 766-2033 or via email.
Frequently Asked Questions
Why has Vaccinex decided to delist from Nasdaq?
Vaccinex is delisting to refocus resources toward the development of their primary product, pepinemab, and after receiving notice regarding potential delisting.
What is pepinemab and how does it work?
Pepinemab is a monoclonal antibody designed to inhibit the SEMA4D pathway, which is involved in neuroinflammation and is being studied for its role in treating Alzheimer’s and various cancers.
What are the future plans of Vaccinex after delisting?
Vaccinex aims to continue its focus on clinical trials for pepinemab and seek partnerships and alternative financing to support its research initiatives.
Is pepinemab safe for patients?
Clinical trials suggest that pepinemab has been well-tolerated, indicating a favorable safety profile for potential candidates in disease therapies.
Who can I contact for more information about Vaccinex?
For inquiries, Elizabeth Evans, PhD, the COO of Vaccinex, is available for contact at (585) 766-2033 or via email.
